Astrocytomas and oligodendrogliomas are primary CNS tumors that remain a challenge to differentiate histologically because of their morphological variability and because there is a lack of reliable differential diagnostic markers. To identify proteins that are differentially expressed between astrocytomas and oligodendrogliomas, the authors analyzed the proteomic expression patterns and identified uniquely expressed proteins in these neoplasms.
Proteomes of astrocytomas and oligodendrogliomas were analyzed using 2D gel electrophoresis and subsequent computerized gel analysis to detect differentially expressed proteins. The proteins were identified using high-performance liquid chromatography accompanied by tandem mass spectrometry. To determine the role of the differentially expressed proteins in astrocytes, undifferentiated glial cell cultures were treated with dibutyryl–cyclic adenosine monophosphate (cAMP).
Two-dimensional gel electrophoresis revealed that glutamine synthetase was differentially expressed in astrocytomas and oligodendrogliomas. Western blot and immunohistochemical analyses confirmed the increased expression of glutamine synthetase in astrocytomas compared with oligodendrogliomas. Whereas glutamine synthetase expression was demonstrated across all grades of astrocytomas (Grade II–IV [15 tumors]) and oligoastrocytomas (4 tumors), it was expressed in only 1 oligodendroglioma (6% [16 tumors]). Treatment of undifferentiated glial cell cultures with dibutyryl-cAMP resulted in astrocyte differentiation that was associated with increased levels of glial fibrillary acidic protein and glutamine synthetase.
These data indicate that glutamine synthetase expression can be used to distinguish astrocytic from oligodendroglial tumors and may play a role in the pathogenesis of astrocytomas.
Abbreviations used in this paper: cAMP = cyclic adenosine monophosphate; GFAP = glial fibrillary acidic protein; HPLC = high-performance liquid chromatography; PAGE = polyacrylamide gel electrophoresis; SDS = sodium dodecyl sulfate.
* Drs. Zhuang and Qi contributed equally to this work.
Address correspondence to: Zhengping Zhuang, M.D., Ph.D, Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, 10 Center Drive, Building 10, Room 3D20, Bethesda, Maryland 20892-1414. email: email@example.com.
Please include this information when citing this paper: published online June 17, 2011; DOI: 10.3171/2011.5.JNS11451.
CairncrossJGUekiKZlatescuMCLisleDKFinkelsteinDMHammondRR: Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst90:1473–14791998
CairncrossJG, UekiK, ZlatescuMC, LisleDK, FinkelsteinDM, HammondRR, : Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. 90:1473–1479, 1998)| false
HerpersMJBudkaH: Glial fibrillary acidic protein (GFAP) in oligodendroglial tumors: gliofibrillary oligodendroglioma and transitional oligoastrocytoma as subtypes of oligodendroglioma. Acta Neuropathol64:265–2721984
HerpersMJ, BudkaH: Glial fibrillary acidic protein (GFAP) in oligodendroglial tumors: gliofibrillary oligodendroglioma and transitional oligoastrocytoma as subtypes of oligodendroglioma. 64:265–272, 1984)| false
SchwechheimerKGassPBerletHH: Expression of oligodendroglia and Schwann cell markers in human nervous system tumors. An immunomorphological study and western blot analysis. Acta Neuropathol83:283–2911992
SchwechheimerK, GassP, BerletHH: Expression of oligodendroglia and Schwann cell markers in human nervous system tumors. An immunomorphological study and western blot analysis. 83:283–291, 1992)| false